News & Updates

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.

Increasing bodyweight may aggravate cardiovascular risk in patients with type 2 diabetes (T2D), a recent Japan study has found.

Drinking a little amount of whey protein before meals helps keep a lid on blood glucose levels of individuals with type 2 diabetes (T2D), as shown in a study.

Among older Southeast Asian type 2 diabetes mellitus patients, severe hypoglycaemia tends to occur with tighter glycaemic control, greater impaired hypoglycaemia awareness, and higher worry scores, regardless of treatment regimens, according to a study.

The use of hormonal replacement therapy (HRT) among postmenopausal women may be associated with a reduced risk of mortality after a COVID-19 diagnosis, according to a retrospective study from Sweden.

Treatment with eldecalcitol, an active vitamin D analogue, does not result in a significant reduction in diabetes incidence and has failed to improve the rate of regression to normoglycaemia relative to placebo among patients with impaired glucose tolerance at high risk for type 2 diabetes (T2D), results of a study have shown.